SCHEDULE: Vanguard Discloses 5.08% Stake in Ideaya Biosciences

Vanguard Capital Management has reported a beneficial ownership of 5.08% in Ideaya Biosciences Inc., holding 4,834,771 shares as of June 30, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 4,834,771 shares of Ideaya Biosciences Inc. common stock.
• This holding represents 5.08% of the class of securities.
• The filing indicates that Vanguard Capital Management has sole dispositive power over 4,834,771 shares and sole voting power over 702,125 shares.
• The reporting date for this ownership stake is June 30, 2026.
• The filing is made under Schedule 13G, indicating it's an informational filing by a passive investor.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership and does not provide operational or financial updates for Ideaya Biosciences.

Positives

• Vanguard's investment signifies confidence in Ideaya Biosciences' long-term prospects, potentially attracting further institutional interest.
• The substantial stake held by a major institutional investor like Vanguard can provide stability and liquidity to the stock.

Negatives

• The filing does not contain any negative information regarding Ideaya Biosciences' performance or operations.

Risks

• As a Schedule 13G filing, it indicates passive ownership. Any shift in Vanguard's investment strategy could lead to significant selling pressure.
• The concentration of ownership by a single large entity could lead to price volatility if that entity decides to divest.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Ideaya Biosciences.

Industry Context

StockSavvy.ai notes that significant stakes taken by large asset managers like Vanguard in biotechnology firms often signal a belief in the company's pipeline or market potential, though this filing specifically pertains to Vanguard's investment position rather than Ideaya's operational outlook.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a reputable firm like Vanguard may be viewed positively, potentially increasing investor confidence.
• Management: The filing does not directly impact management's operational responsibilities but signifies external validation of the company's market position.

Next Steps

• Vanguard Capital Management will continue to hold its shares in Ideaya Biosciences, subject to its investment strategy.
• Ideaya Biosciences will continue its operations and business development activities.

Key Dates

Keywords

Ideaya Biosciences, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology